The cancer supportive care drugs market is foreseen to witness significant developments in the forecast period. As per the research report, the market is likely to register a single-digit CAGR growth. This is majorly attributed to the rising clinical trials regarding cancer treatments which are foreseen to boost the demand in the global cancer supportive care products market.
Treatment for cancer is not an easy method. It has several side effects such as fatigue, pain, loss of self-esteem, menopausal symptoms, low confidence, change in sexuality, cognitive changes, fertility problems, depression, lymphedema, and many more. Among these, some side effects turn out to be a serious medical issue that requires to be treated and the other ones are just disturbing, inconvenient, or upsetting, however, not that harmful. An increase in such side-effects of the disease and the rising need to manage them successfully is contributing to the global cancer supportive care drugs market.
Nevertheless, the discovery of biosimilars and increased spending on R&D activities are foreseen to surge the demand in the market. However, dealing with admin issues is among the key factors that are estimated to hinder the growth of the global market within the forecast period. In addition, the key players operating in the global cancer supportive care products market are expected to witness new opportunities in densely populated nations across the globe coupled with increasing investments in the research activities.
The global cancer supportive care drugs market is broadly categorized into drug class, cancer type, and region. The drug class segment is divided into Erythropoietin-Stimulating Agents (ESA), Non-Steroidal Anti-Inflammatory Drugs (NSAID), Granulocyte-Colony Stimulating Factors (G-CSF), Antiemetic’s, Opioids, Bisphosphonates, and Others. On the basis of type segment, the global market is segregated into prostate cancer, lung cancer, breast cancer, melanoma, and other cancers.
Based on geography, the global cancer supportive care drugs market is led by North America due to the increased number of people suffering from different types of cancers. In addition, several key players are also based in the countries of the region, contributing in the region’s growth.
Besides this, Asia Pacific is also foreseen to register a promising growthin the coming years, especially from India and China that are among the leading nations emerging as the market accelerators. In addition, increased research on biosimilars, low-cost base, and advantageous healthcare reforms are likely to bolster the regional market growth. The current cancer supportive care drugs are effective in providing only symptomatic relief. For example, analgesic drugs that have low tolerance risk and abuse are one of the unmet needs in the market.
The leading players in the global cancer supportive care drugs market include Amgen, Roche, Merck, Johnson & Johnson, Helsinn Healthcare, Tesaro, and Heron Pharma. To cite, a China-based Fintech startup named Ice Kredit got finance of US$35 million in Series C2 to work further on the research activities for cancer supportive care drugs.